NEW HOPE FOR ALS PATIENTS Stem Cells Breakthrough! Dramatic change in patient with ALS and MG following BrainStorms Therapy. Please read the info below. July 3, 2012 - Israeli Channel 2 reports: Dramatic Change in Patient with ALS and MG following Compassionate Use of BrainStorms Nurown™ Cell Therapy NY, Petach Tikva, July 2, 2012. -- BrainStorm Cell Therapeutics Inc. (OTC BB: BCLI), Israeli Channel 2 TV interviewed today a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorms NurOwn cell therapy. Due to the rare disease combination of MG and ALS, this patient was approved for compassionate treatment with BrainStorms NurOwn cell therapy says Professor Dimitrios Karussis of the Neurology Department at The Hadassah Medical Center in Jerusalem, and Principal Investigator of BrainStorms current Phase I/II clinical trial. Within a few weeks following injection with NurOwn cells, the patient showed dramatic improvement in a variety of functions including breathing, speech, walking, muscular strength, and overall well-being. While we cannot draw scientific conclusions based on the outcome of an individual patient, these results are extremely encouraging. We are moved by the remarkable results observed following treatment with NurOwn, said Professor Avi Israeli, BrainStorms Chairman of the Board. We are hopeful that we will continue to see this kind of improvement in all the patients participating in our current and future clinical trials. In January 2012 the Company reported initial safety data from the first four patients in BrainStorms ALS Phase I/II human clinical trial, indicating that treatment with NurOwn did not present any significant side effects and demonstrated some beneficial clinical effects. After reviewing this safety data, the Hadassah Medical Center ethical committee granted approval for the trial to continue. Interim results for the first 12 patients are expected in July 2012. BrainStorm expects to expand its ALS clinical development into the United States. Orphan-drug designation for NurOwn has been granted by the US Food and Drug Administration. In addition, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions. youtu.be/oImcvUbCPdQ
Posted on: Mon, 25 Aug 2014 04:07:35 +0000
Recently Viewed Topics
© 2015